HC Wainwright Lifts Earnings Estimates for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Stock analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of Sensus Healthcare in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.08 for the quarter, up from their prior estimate of $0.03. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.20 EPS.

Separately, Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $8.94 on Wednesday. Sensus Healthcare has a 1-year low of $2.05 and a 1-year high of $9.20. The stock has a market cap of $146.53 million, a P/E ratio of 15.60 and a beta of 1.04. The firm has a 50-day moving average of $6.47 and a two-hundred day moving average of $6.03.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its position in shares of Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after purchasing an additional 93,511 shares during the last quarter. Chapin Davis Inc. bought a new stake in shares of Sensus Healthcare in the 2nd quarter valued at approximately $53,000. Renaissance Technologies LLC raised its position in shares of Sensus Healthcare by 34.4% during the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after acquiring an additional 100,294 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Sensus Healthcare during the second quarter worth $156,000. Finally, Sachetta LLC increased its stake in Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after purchasing an additional 13,544 shares during the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.